Healthcare Industry News: Adaptive Radiation Therapy
News Release - June 27, 2012
Accuray Announces Installation of TomoTherapy(R) System at University of California, San FranciscoImage-Guided, Intensity Modulated Radiation Therapy Added to UCSF's Suite of Treatment Options for Cancer Patients
SUNNYVALE, Calif., June 27, 2012 -- (Healthcare Sales & Marketing Network) -- Accuray Incorporated (ARAY), the premier radiation oncology company, announced today that doctors at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center in San Francisco, Calif. are now treating cancer patients with the TomoTherapy® System, the only radiation therapy system specifically designed for integrated, daily, 3D image-guided, intensity modulated radiation therapy (IG-IMRT). The TomoTherapy System, which stands out as one of the most advanced and comprehensive radiation therapy technologies available, is capable of treating a broad range of tumors—from the most common to the most complex—with speed and precision while reducing radiation exposure to surrounding healthy tissue. The TomoTherapy System will help clinicians at UCSF to treat a broader range of tumors as well as personalize and expand radiation treatment options available to cancer patients
"At UCSF, we are dedicated to offering the most advanced cancer treatment options available in order to provide accurate and highly individualized care for each patient," said Mack Roach, III, Professor Radiation Oncology and Urology, Chair Radiation Oncology at UCSF Helen Diller Family Comprehensive Cancer Center. "Having a dedicated system built from the ground up to deliver IMRT treatments is a valuable addition to our suite of cancer care technologies."
UCSF installed its TomoTherapy System in May 2012 to replace a standard linear accelerator and to date has treated malignant tumors in the prostate, rectum, bladder and gynecological treatments. In addition to its TomoTherapy System, the Center offers the CyberKnife® Robotic Radiosurgery System which is also manufactured by Accuray, as well as a full brachytherapy program, a proton beam system and other stereotactic body radiation therapy and radiosurgery systems to ensure each patient has access to the best treatment option for their unique case.
The TomoTherapy System utilizes daily computed tomography (CT) imaging to identify the exact position of the tumor on each day of treatment, enabling clinicians to customize treatment for each patient, minimize radiation exposure to healthy tissue and critical structures and reduce side effects. Unlike conventional systems, which allow radiation to be delivered from only a few directions, the TomoTherapy System rotates as the patient moves through the system resulting in treatments that can be delivered continuously to the tumor from hundreds of angles. More beam directions give physicians more control in how the treatment is delivered—and more assurance that the dose will be confined to the tumor, reducing the risk of short- and long-term side effects.
Accuray Incorporated (ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company's leading edge technologies – the CyberKnife and TomoTherapy Systems – are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and Adaptive Radiation Therapy. To date 635 systems have been installed in leading hospitals around the world. For more information, please visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to reduced radiation exposure, clinical applications, and clinical benefits. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading "Risk Factors" in the Company's report on Form 10-K for fiscal year 2011, and its reports on Form 10-Q for the first, second and third quarters of fiscal 2012. Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsAccuray Educates Radiation Oncology Practices on the Potential Impact of the Proposed Alternative Payment Model (RO-APM)
Swiss Medical Network Advances Cancer Care in Switzerland with Multi-System Agreement for Accuray Radiation Therapy Systems and RaySearch Oncology Software Systems
Accuray Launches Synchrony(R) Motion Tracking and Correction Technology for the Radixact(R) System